37504-94-2

Upstream product

• 86547-30-0 p-Toluolsulfonsaeure-<(2S)-2,3-dihydroxy-3-methylbutyl>ester 
• 77-76-9 2,2-dimethoxy-propane 
• 86547-26-4 Benzoesaeure-<(2S)-2,3-dihydroxy-3-methylbutyl>ester 
• 86562-71-2 2-<(S)-2,2-dimethyl-1,3-dioxolane-4-yl>-2-propanol 
• 86562-72-3 S(-)methyl-3 butanetriol-1,2,3 
• 37504-92-0 (4'S)-(2',2',5',5'-tetramethyl-1',3'-dioxolan-4'-yl)methanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1093988-65-8 methyl 2-methyl-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzoate 
• 1093988-66-9 2-methyl-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzohydrazide 
• 1093988-30-7 methyl 4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzoate 
• 1093988-32-9 3-chloro-5-[(6-chloro-3-{[5-(4-{[(2S)-2,3-dihydroxy-3-methylbutyl]oxy}phenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1093988-31-8 4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzohydrazide 
• 1093988-29-4 3-chloro-5-{[6-chloro-2-fluoro-3-({5-[4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)phenyl]-1,3,4-oxadiazol-2-yl}methyl)phenyl]oxy}benzonitrile 
• 1093988-73-8 2-chloro-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzohydrazide 
• 1093988-72-7 methyl 2-chloro-4-({[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}oxy)benzoate 
• 86547-30-0 p-Toluolsulfonsaeure-<(2S)-2,3-dihydroxy-3-methylbutyl>ester 
• 1094345-49-9 3-chloro-5-({6-chloro-3-[(5-{1-[(2S)-2,3-dihydroxy-3-methylbutyl]-3,5-dimethyl-1H-pyrazol-4-yl}-1,3,4-oxadiazol-2-yl)methyl]-2-fluorophenyl}oxy)benzonitrile 
• 1094347-72-4 3-chloro-5-[(6-chloro-3-{[5-(3,5-dimethyl-1-{[(4S)-2,2,5,5-tetramethyl-1,3-dioxolan-4-yl]methyl}-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Optically Active C5-Synthons for the Synthesis of Naturally Occurring Terpenes

The optically active synthons (S)-22, (R)-23, (R)-25 and (R)-26 were prepared from L-serine.Furthermore the tertiary alcohol 6 was synthesized from L-serine (-> (S)-6) and D-mannitol (-> (R)-6).These compounds are suitable for the synthesis of optically active natural products.